The following pages contain information regarding the share capital increase of Voluntis. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please select your country of residence to access such information.

First day of trading of Voluntis shares on the Euronext Growth Paris market

Cambridge (United States) and Paris (France), 17 February 2021
  • New ticker: ALVTX
  • ISIN code unchanged: FR0004183960

Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in the field of digital therapeutics, announces the listing of Voluntis shares on the Euronext Growth Paris market as of today.  

The new ticker of Voluntis share is ALVTX. The ISIN code remains unchanged: FR0004183960. In addition, Voluntis shares remain eligible for PEAs and PEA-SMEs.

The information document relating to the transfer of the listing of Voluntis shares on the Euronext Growth Paris market is available on the following page of the company's website: https://www.voluntis.com/fr/investors as well as on the Euronext website. 

Next meeting: publication of the 2020 annual results on March 30, 2021, after the close of trading.

About Voluntis

Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms.

Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.